OverweightNCT07895563
A Study to Evaluate the Effects of a Dietary Supplement on Weight Management and Appetite Control
A study testing MN Nutra GeLiPthin-1™ Dietary Supplement in people with Overweight and Obesity, run by MNnutra at 1 site in United States.
Trial summary
This is a randomized, double-blind, placebo-controlled, decentralized clinical trial evaluating the effects of MN Nutra GeLiPthin-1™, a multi-ingredient dietary supplement, on body weight, BMI, waist circumference, appetite, satiety, and energy levels in overweight and obese adults over six weeks. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Overweight, Obesity, Weight Management
- What is being tested?
- MN Nutra GeLiPthin-1™ Dietary Supplement
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 170 participants
- Where
- 1 siteUnited States
- Study dates
- 27 Aug 2026to Oct 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Male or female.
- Aged 18 to 65 years.
- Anyone currently experiencing issues regarding all of the following: healthy weight management
- appetite management and/or food cravings
- energy levels.
- Resides in the United States.
Show all 11Show fewer
- Body Mass Index (BMI) ≥ 27.0 and < 35.0 kg/m².
- Anyone who is generally healthy - does not live with any uncontrolled chronic disease.
- Willing to follow the study protocol.
- Willing to maintain current diet, physical activity, and lifestyle habits for the study duration.
- Willing to abstain from alcohol consumption during the study period.
Who cannot join
- Current use or use within three months of GLP-1 receptor agonists (e.g., semaglutide/Ozempic/Wegovy, liraglutide/Saxenda/Victoza, tirzepatide/Mounjaro/Zepbound, or dulaglutide/Trulicity) or any prescription weight-loss medication.
- Concurrent use of overlapping weight-management dietary supplements that participants are unwilling to discontinue for the study duration.
- Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
- Anyone who is currently undergoing treatment for cancer, or has had a serious illness requiring hospitalization in the last 3 months.
- Currently undergoing or planning to undergo any significant medical procedures in the next six weeks.
- Currently enrolled in a medically supervised weight-loss program, or has a history of bariatric surgery within the past 12 months.
Show all 15Show fewer
- Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period).
- Heavy drinkers or drug users.
- A heavy drinker is considered to be a woman who drinks 8 or more alcoholic drinks per week or a man who drinks 15 or more alcoholic drinks per week.
- Active or historical eating disorder (e.g., anorexia nervosa, bulimia nervosa, binge eating disorder).
- Known allergy or hypersensitivity to any ingredient in the study product or placebo.
- Diagnosed diabetes (type 1 or type 2) or use of insulin or antidiabetic medications (e.g., metformin).
- Known cardiovascular disease or uncontrolled hypertension.
- Clinically significant liver disease or known abnormal liver function.
- Currently testing, or planning to in the next six weeks, a product for another research study.
Trial locations and contacts
1 site in 1 country.
About this study
This is a randomized, double-blind, placebo-controlled, decentralized clinical trial evaluating the effects of MN Nutra GeLiPthin-1™, a multi-ingredient dietary supplement, on body weight, BMI, waist circumference, appetite, satiety, and energy levels in overweight and obese adults over six weeks. A total of 170 generally healthy adults aged 18-65 years with a BMI of 27.0-35.0 kg/m² will be randomized 1:1 to receive either the active supplement or a matching placebo.
Participants will take three capsules orally twice daily for six weeks. All study activities are conducted remotely, including electronic consent, self-administered anthropometric measurements using a sponsor-provided Withings Scale and tape measure, and weekly online questionnaires via the Citruslabs digital study platform. The primary outcome is change in body weight from Baseline to Week 6.
- Conditions
- Overweight, Obesity, Weight Management, Appetite Control
- Being tested
- MN Nutra GeLiPthin-1™ Dietary Supplement, Placebo
- Medical subject headings
- Overweight, Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MN Nutra GeLiPthin-1™ Dietary SupplementDietary supplement
Participants will take three capsules orally twice daily for six weeks. All study activities are conducted remotely, including electronic consent, self-administered anthropometric measurements using a sponsor-provided Withings Scale and tape measure, and weekly online questionnaires via the Citruslabs digital study platform.
PlaceboDietary supplement
Participants receive matching placebo capsules containing microcrystalline cellulose (quantity sufficient to match active fill weight of 1920 mg per dose)
| Study group | Role | What they receive |
|---|---|---|
| Treatment A | Experimental | Not described Receives: Dietary Supplement: MN Nutra GeLiPthin-1™ Dietary Supplement |
| Placebo - Placebo Comparator | Placebo comparator | Not described Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Body Weight
Change from Baseline to Week 6 in body weight (kg) and percentage change in body weight, measured using a sponsor-provided Withings Scale (daily for three consecutive days at each timepoint; values averaged)
Measured: Baseline to Week 6
Secondary outcomes (12)
Change in Waist Circumference
Change from Baseline to Week 6 in waist circumference (cm), measured using a sponsor-provided tape measure with CRC-guided instructions during a video call (three measurements taken and averaged)
Measured: Baseline to Week 6
Change in BMI
Change from Baseline to Week 6 in BMI (kg/m²), calculated using weight measured by Withings Scale and self-reported height collected at Baseline
Measured: Baseline to Week 6
Change in Self-Reported Appetite
Change from Baseline to Week 6 in self-reported appetite assessed using questionnaires including the Food Craving Questionnaire reduced (FCQ-T reduced), administered via the Citruslabs study platform
Measured: Baseline to Week 6
Change in Self-Reported Between-Meal Hunger
Change from Baseline to Week 6 in between-meal hunger assessed using questionnaires including the Food Craving Questionnaire reduced (FCQ-T reduced), administered via the Citruslabs study platform
Measured: Baseline to Week 6
Change in Self-Reported Post-Meal Fullness
Change from Baseline to Week 6 in post-meal fullness assessed using questionnaires including the Food Craving Questionnaire reduced (FCQ-T reduced), administered via the Citruslabs study platform
Measured: Baseline to Week 6
Change in Perceived Control Over Eating
Change from Baseline to Week 6 in perceived control over eating assessed using questionnaires including the Food Craving Questionnaire reduced (FCQ-T reduced), administered via the Citruslabs study platform
Measured: Baseline to Week 6
Change in Participant Perceptions of Effects on Appetite
Changes in participant-reported perceptions of the product's effect on appetite, assessed via self-reported questionnaire on the Citruslabs study platform
Measured: Week 1 to Week 6
Change in Participant Perceptions of Effects on Satiety
Changes in participant-reported perceptions of the product's effect on satiety, assessed via self-reported questionnaire on the Citruslabs study platform
Measured: Week 1 to Week 6
Change in Participant Perceptions of Effects on Eating Control
Changes in participant-reported perceptions of the product's effect on eating control, assessed via self-reported questionnaire on the Citruslabs study platform
Measured: Week 1 to Week 6
Change in Participant Perceptions of Effects on Energy Levels
Changes in participant-reported perceptions of the product's effect on energy levels, assessed via self-reported questionnaire on the Citruslabs study platform
Measured: Week 1 to Week 6
Change in Participant Perceptions of Overall Well-Being
Changes in participant-reported perceptions of the product's effect on overall well-being, assessed via self-reported questionnaire on the Citruslabs study platform
Measured: Week 1 to Week 6
Incidence of Treatment-Emergent Adverse Events
Incidence, severity, and relatedness of treatment-emergent adverse events (TEAEs), collected via adverse event reporting through the study platform and direct participant communication
Measured: Baseline through Week 6
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Oct 2026
- Study start27 Aug 2026
- Primary completionOct 2026 (estimated)
- Study completionOct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for OverweightStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 170 participants (estimated)
Sponsor and investigators
- Lead sponsor
- MNnutra
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07895563
- Sponsor's protocol ID
- MNNUT-72620
- Status last verified
- Oct 2026
- First submitted
- 19 Oct 2026
- Last updated
- 26 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Study to Evaluate the Effects of a Dietary Supplement on Weight Management and Appetite Control
- ClinicalTrials.gov ID
- NCT07895563
- Acronym / sponsor ID
- MNNUT-72620
- Conditions
- Overweight, Obesity, Weight Management, Appetite Control
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 170 participants (estimated)
- Lead sponsor
- MNnutraIndustry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Study start
- 27 Aug 2026 (actual)
- Primary completion
- Oct 2026 (estimated)
- Study completion
- Oct 2026 (estimated)
- First posted
- 26 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a randomized, double-blind, placebo-controlled, decentralized clinical trial evaluating the effects of MN Nutra GeLiPthin-1™, a multi-ingredient dietary supplement, on body weight, BMI, waist circumference, appetite, satiety, and energy levels in overweight and obese adults over six weeks. A total of 170 generally healthy adults aged 18-65 years with a BMI of 27.0-35.0 kg/m² will be randomized 1:1 to receive either the active supplement or a matching placebo.
Participants will take three capsules orally twice daily for six weeks. All study activities are conducted remotely, including electronic consent, self-administered anthropometric measurements using a sponsor-provided Withings Scale and tape measure, and weekly online questionnaires via the Citruslabs digital study platform. The primary outcome is change in body weight from Baseline to Week 6.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Treatment A | Experimental | Dietary Supplement: MN Nutra GeLiPthin-1™ Dietary Supplement |
| Placebo - Placebo Comparator | Placebo comparator | Dietary Supplement: Placebo |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Male or female.
- Aged 18 to 65 years.
- Anyone currently experiencing issues regarding all of the following: healthy weight management
- appetite management and/or food cravings
- energy levels.
Key exclusion criteria (15 listed)
- Current use or use within three months of GLP-1 receptor agonists (e.g., semaglutide/Ozempic/Wegovy, liraglutide/Saxenda/Victoza, tirzepatide/Mounjaro/Zepbound, or dulaglutide/Trulicity) or any prescription weight-loss medication.
- Concurrent use of overlapping weight-management dietary supplements that participants are unwilling to discontinue for the study duration.
- Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
- Anyone who is currently undergoing treatment for cancer, or has had a serious illness requiring hospitalization in the last 3 months.
- Currently undergoing or planning to undergo any significant medical procedures in the next six weeks.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MN Nutra GeLiPthin-1™ Dietary SupplementParticipants will take three capsules orally twice daily for six weeks. All study activities are conducted remotely, including electronic consent, self-administered anthropometric measurements using a sponsor-provided Withings Scale and tape measure, and weekly online questionnaires via the Citruslabs digital study platform. | Dietary supplement | Treatment A |
| PlaceboParticipants receive matching placebo capsules containing microcrystalline cellulose (quantity sufficient to match active fill weight of 1920 mg per dose) | Dietary supplement | Placebo - Placebo Comparator |
Primary outcome
Change in Body Weight
Time frame: Baseline to Week 6
Change from Baseline to Week 6 in body weight (kg) and percentage change in body weight, measured using a sponsor-provided Withings Scale (daily for three consecutive days at each timepoint; values averaged)
12 secondary outcomes
Change in Waist Circumference
Time frame: Baseline to Week 6
Change in BMI
Time frame: Baseline to Week 6
Change in Self-Reported Appetite
Time frame: Baseline to Week 6
Change in Self-Reported Between-Meal Hunger
Time frame: Baseline to Week 6
Change in Self-Reported Post-Meal Fullness
Time frame: Baseline to Week 6
Change in Perceived Control Over Eating
Time frame: Baseline to Week 6
Change in Participant Perceptions of Effects on Appetite
Time frame: Week 1 to Week 6
Change in Participant Perceptions of Effects on Satiety
Time frame: Week 1 to Week 6
Change in Participant Perceptions of Effects on Eating Control
Time frame: Week 1 to Week 6
Change in Participant Perceptions of Effects on Energy Levels
Time frame: Week 1 to Week 6
Change in Participant Perceptions of Overall Well-Being
Time frame: Week 1 to Week 6
Incidence of Treatment-Emergent Adverse Events
Time frame: Baseline through Week 6
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Oct 2026.
Related trials for Overweight
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing MN Nutra GeLiPthin-1™ Dietary Supplement in people with Overweight and Obesity, run by MNnutra at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 26 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Body Weight (time frame: Baseline to Week 6). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2026.